Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone replacement in ESRD patients with hypogonadism
NCT02712944Phase 1Terminated
- Sponsor
- Texas Tech University Health Sciences Center
- Start
- Jul 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of testosterone in Hypogonadism, sponsored by Texas Tech University Health Sciences Center. Primary endpoint: Change in dosage of Erythropoietin stimulating agents at 6 months. Started Jul 2016; status: terminated.
02
Drugs
testosterone
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT02712944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712944.